Telomir Pharmaceuticals Unveils Breakthrough Study on Telomir-1's Enzyme Inhibition

Boston, Thursday, 7 August 2025.
Telomir Pharmaceuticals revealed Telomir-1’s potential in treating cancer and autoimmune diseases by inhibiting key enzymes involved in epigenetic regulation. This breakthrough positions Telomir-1 as a novel therapeutic contender.